Prasad: most surrogate endpoints in cancer trials correlate poorly with survival
A systematic review of 36 trial-level meta-analyses found that in over half the surrogate endpoint (response rate, progression-free survival) had a low correlation with overall survival, and only about a quarter showed a strong correlation.
Prasad and colleagues searched for trial-level meta-analyses that quantified the correlation between a surrogate endpoint and overall survival across randomised oncology trials. They identified 36 articles covering 65 surrogate-survival associations in many tumour types and settings.
Using a conventional threshold, 52% of reported correlations were low (r below 0.7), 25% medium (0.7 to 0.85) and 23% high (0.85 or more). Correlations were weakest in the metastatic setting and for response rate. A companion analysis by the same group (Kim and Prasad, JAMA Internal Medicine 2015) showed that of 54 FDA cancer drug approvals in 2008-2012, 36 were based on surrogates, and after a median 4.4 years only 5 had demonstrated an overall survival benefit.
The work catalysed the debate over accelerated approval, the FDA's 2023-2025 reforms requiring confirmatory trials to be under way at approval, and the growing use of quality-of-life and patient-reported endpoints.
- 36 trial-level meta-analyses covering 65 surrogate-OS associations reviewed
- 52% of surrogate-survival correlations were low (r below 0.7), 25% medium, 23% high
- Response rate and PFS in the metastatic setting were the weakest surrogates
- Companion analysis: of 36 approvals on surrogates (2008-2012), 5 later showed an OS benefit, 18 failed to or were not tested, and 13 remained unknown
A drug that shrinks tumours or delays progression on scans has not necessarily been shown to help patients live longer or better. Patients and clinicians should ask what the endpoint was; regulators should insist on timely confirmatory trials; and trialists should validate surrogates before relying on them.
- Trial-level correlation is only one way to validate a surrogate; some settings (adjuvant DFS in colon cancer) have well-validated surrogates
- Low correlation may reflect crossover and post-progression therapy diluting the OS signal rather than a useless surrogate
- The review depended on published meta-analyses and their heterogeneous methods
- PFS can be a meaningful endpoint in itself when progression is symptomatic and treatment is tolerable
Pages like this
not linked directly; found by shared links- IdeaProvisional prices for surrogate-endpoint approvals, reset when survival data arrive
Shares Accelerated approval, Overall survival (OS), Regulatory divergence between regions, Progression-free survival (PFS).
- IdeaPublish the disagreement between trial doctors and independent reviewers for every trial
Shares RECIST, Hazard ratio (HR), Progression-free survival (PFS), Trial design, endpoints and cost.
- IdeaTime to treatment failure and quality of life as co-primary endpoints in non-curative trials
Shares Patients lack understanding, navigation and agency, Overall survival (OS), Progression-free survival (PFS), Trial design, endpoints and cost.
- IdeaPre-specified crossover-adjusted survival in every trial that allows crossover
Shares Hazard ratio (HR), Overall survival (OS), Trial design, endpoints and cost.
- IdeaSeamless phase 2/3 with pre-registered go rules as the default for new agents
Shares Overall survival (OS), Progression-free survival (PFS), Trial design, endpoints and cost.
- IdeaRequire a randomised phase 2 before any phase 3
Shares Objective response rate (ORR), Progression-free survival (PFS), Trial design, endpoints and cost.
- PersonNathan Cherny
Shares Win-ratio endpoints that weigh survival, toxicity and quality of life together, Power trials to detect a benefit patients would value, not the smallest detectable one.
- IdeaReport time toxicity, the days a treatment consumes, in every trial and decision aid
Shares Patients lack understanding, navigation and agency, Overall survival (OS), Progression-free survival (PFS).